TWI409070B - 用於調節ｔｒｐｖ３功能之化合物 - Google Patents

Info

Publication number

TWI409070B

TWI409070B TW095140730A TW95140730A TWI409070B TW I409070 B TWI409070 B TW I409070B TW 095140730 A TW095140730 A TW 095140730A TW 95140730 A TW95140730 A TW 95140730A TW I409070 B TWI409070 B TW I409070B

Authority

TW

Taiwan

Prior art keywords

pain

trpv3

compound

group

use according

Prior art date

2005-11-04

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 291
• 208000002193 Pain Diseases 0.000 claims abstract description 272
• 230000036407 pain Effects 0.000 claims abstract description 243
• 102000003568 TRPV3 Human genes 0.000 claims abstract 29
• 101150043371 Trpv3 gene Proteins 0.000 claims abstract 29
• 125000000217 alkyl group Chemical group 0.000 claims description 175
• -1 decylamino, decylamino Chemical group 0.000 claims description 124
• 239000003112 inhibitor Substances 0.000 claims description 113
• 208000024891 symptom Diseases 0.000 claims description 96
• 229910052799 carbon Inorganic materials 0.000 claims description 74
• 125000001424 substituent group Chemical group 0.000 claims description 73
• 239000001257 hydrogen Substances 0.000 claims description 69
• 229910052739 hydrogen Inorganic materials 0.000 claims description 69
• 125000003545 alkoxy group Chemical group 0.000 claims description 61
• 150000003839 salts Chemical class 0.000 claims description 60
• 238000011282 treatment Methods 0.000 claims description 59
• 229910052736 halogen Inorganic materials 0.000 claims description 57
• 150000002367 halogens Chemical class 0.000 claims description 57
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 57
• 239000003795 chemical substances by application Substances 0.000 claims description 51
• 150000002431 hydrogen Chemical class 0.000 claims description 49
• 230000001404 mediated effect Effects 0.000 claims description 45
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 44
• 206010031009 Oral pain Diseases 0.000 claims description 42
• 150000002148 esters Chemical class 0.000 claims description 41
• 125000003118 aryl group Chemical group 0.000 claims description 38
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
• 239000003814 drug Substances 0.000 claims description 35
• 125000003342 alkenyl group Chemical group 0.000 claims description 32
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 32
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 32
• 150000002576 ketones Chemical class 0.000 claims description 31
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 30
• 206010061218 Inflammation Diseases 0.000 claims description 29
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
• 230000004054 inflammatory process Effects 0.000 claims description 29
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 28
• 102000003566 TRPV1 Human genes 0.000 claims description 27
• 101150016206 Trpv1 gene Proteins 0.000 claims description 27
• 125000000304 alkynyl group Chemical group 0.000 claims description 27
• 208000004296 neuralgia Diseases 0.000 claims description 26
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 26
• 150000001299 aldehydes Chemical class 0.000 claims description 25
• 208000021722 neuropathic pain Diseases 0.000 claims description 25
• 239000012453 solvate Substances 0.000 claims description 24
• 206010033645 Pancreatitis Diseases 0.000 claims description 23
• 125000001072 heteroaryl group Chemical group 0.000 claims description 23
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
• 206010011224 Cough Diseases 0.000 claims description 21
• 230000005764 inhibitory process Effects 0.000 claims description 21
• 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 21
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 19
• 125000004414 alkyl thio group Chemical group 0.000 claims description 19
• 208000000094 Chronic Pain Diseases 0.000 claims description 18
• 201000004624 Dermatitis Diseases 0.000 claims description 17
• 239000005977 Ethylene Substances 0.000 claims description 17
• 230000001154 acute effect Effects 0.000 claims description 17
• MQNAOOIFODUDES-UHFFFAOYSA-N o-decylhydroxylamine Chemical compound CCCCCCCCCCON MQNAOOIFODUDES-UHFFFAOYSA-N 0.000 claims description 17
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
• 125000005647 linker group Chemical group 0.000 claims description 16
• 206010058019 Cancer Pain Diseases 0.000 claims description 15
• 206010065390 Inflammatory pain Diseases 0.000 claims description 15
• 230000002401 inhibitory effect Effects 0.000 claims description 15
• 102000003678 AMPA Receptors Human genes 0.000 claims description 14
• 108090000078 AMPA Receptors Proteins 0.000 claims description 14
• 208000001640 Fibromyalgia Diseases 0.000 claims description 13
• 208000011580 syndromic disease Diseases 0.000 claims description 13
• 102000003570 TRPV5 Human genes 0.000 claims description 12
• 102000003569 TRPV6 Human genes 0.000 claims description 12
• 101150096736 TRPV6 gene Proteins 0.000 claims description 12
• 101150034091 Trpv5 gene Proteins 0.000 claims description 12
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 229940124530 sulfonamide Drugs 0.000 claims description 12
• 206010021639 Incontinence Diseases 0.000 claims description 11
• 150000001540 azides Chemical class 0.000 claims description 11
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
• 230000002438 mitochondrial effect Effects 0.000 claims description 11
• 230000035945 sensitivity Effects 0.000 claims description 11
• 150000003456 sulfonamides Chemical class 0.000 claims description 11
• 208000019695 Migraine disease Diseases 0.000 claims description 10
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 10
• 206010037660 Pyrexia Diseases 0.000 claims description 10
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 10
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 9
• 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 claims description 9
• 208000001294 Nociceptive Pain Diseases 0.000 claims description 9
• 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims description 9
• 201000004681 Psoriasis Diseases 0.000 claims description 9
• 208000005298 acute pain Diseases 0.000 claims description 9
• 150000003568 thioethers Chemical class 0.000 claims description 9
• 208000033830 Hot Flashes Diseases 0.000 claims description 8
• 206010060800 Hot flush Diseases 0.000 claims description 8
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 8
• 108091006293 Uniporters Proteins 0.000 claims description 8
• 102000037089 Uniporters Human genes 0.000 claims description 8
• 229940121375 antifungal agent Drugs 0.000 claims description 8
• 239000003443 antiviral agent Substances 0.000 claims description 8
• 208000010668 atopic eczema Diseases 0.000 claims description 8
• 206010027599 migraine Diseases 0.000 claims description 8
• 201000008482 osteoarthritis Diseases 0.000 claims description 8
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 7
• 239000000058 anti acne agent Substances 0.000 claims description 6
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
• 230000002682 anti-psoriatic effect Effects 0.000 claims description 6
• 229940124340 antiacne agent Drugs 0.000 claims description 6
• 239000003429 antifungal agent Substances 0.000 claims description 6
• 125000004432 carbon atom Chemical group C* 0.000 claims description 6
• 239000004075 cariostatic agent Substances 0.000 claims description 6
• 239000003410 keratolytic agent Substances 0.000 claims description 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
• 230000002265 prevention Effects 0.000 claims description 6
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 5
• 208000024720 Fabry Disease Diseases 0.000 claims description 5
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 5
• 230000001028 anti-proliverative effect Effects 0.000 claims description 5
• 230000001153 anti-wrinkle effect Effects 0.000 claims description 5
• 239000004599 antimicrobial Substances 0.000 claims description 5
• 229940125684 antimigraine agent Drugs 0.000 claims description 5
• 239000002282 antimigraine agent Substances 0.000 claims description 5
• 239000002904 solvent Substances 0.000 claims description 5
• 125000006575 electron-withdrawing group Chemical group 0.000 claims description 4
• VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical group OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 4
• MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 claims description 3
• SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 3
• 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 2
• 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 8
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 3
• CUTHIPXCPQYUFV-UHFFFAOYSA-N S-decylthiohydroxylamine Chemical compound C(CCCCCCCCC)SN CUTHIPXCPQYUFV-UHFFFAOYSA-N 0.000 claims 2
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
• ZNPKAOCQMDJBIK-UHFFFAOYSA-N nitrocyanamide Chemical compound [O-][N+](=O)NC#N ZNPKAOCQMDJBIK-UHFFFAOYSA-N 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 67
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 109
• 201000010099 disease Diseases 0.000 description 98
• 239000005557 antagonist Substances 0.000 description 92
• 230000006870 function Effects 0.000 description 91
• 230000006378 damage Effects 0.000 description 84
• 208000014674 injury Diseases 0.000 description 59
• 230000000694 effects Effects 0.000 description 58
• 208000027418 Wounds and injury Diseases 0.000 description 52
• 239000000203 mixture Substances 0.000 description 48
• 239000011575 calcium Substances 0.000 description 44
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 36
• 210000004027 cell Anatomy 0.000 description 36
• 229910052791 calcium Inorganic materials 0.000 description 34
• 208000025865 Ulcer Diseases 0.000 description 33
• 125000000623 heterocyclic group Chemical group 0.000 description 31
• 206010028980 Neoplasm Diseases 0.000 description 30
• 150000002500 ions Chemical class 0.000 description 30
• 239000002253 acid Substances 0.000 description 29
• 210000003491 skin Anatomy 0.000 description 25
• 241001465754 Metazoa Species 0.000 description 24
• 229940079593 drug Drugs 0.000 description 24
• 108091006146 Channels Proteins 0.000 description 23
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 23
• 201000011510 cancer Diseases 0.000 description 23
• 208000007117 Oral Ulcer Diseases 0.000 description 22
• 150000007970 thio esters Chemical class 0.000 description 21
• 208000015181 infectious disease Diseases 0.000 description 20
• 229940002612 prodrug Drugs 0.000 description 20
• 239000000651 prodrug Substances 0.000 description 20
• 239000002585 base Substances 0.000 description 19
• 108090000765 processed proteins & peptides Proteins 0.000 description 19
• 231100000397 ulcer Toxicity 0.000 description 19
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 18
• 108090000862 Ion Channels Proteins 0.000 description 18
• 102000004310 Ion Channels Human genes 0.000 description 18
• 238000009472 formulation Methods 0.000 description 18
• 210000004209 hair Anatomy 0.000 description 18
• 102000004196 processed proteins & peptides Human genes 0.000 description 18
• 108090000623 proteins and genes Proteins 0.000 description 18
• 239000011734 sodium Substances 0.000 description 18
• 229910052708 sodium Inorganic materials 0.000 description 18
• 229920001184 polypeptide Polymers 0.000 description 17
• 235000018102 proteins Nutrition 0.000 description 17
• 102000004169 proteins and genes Human genes 0.000 description 17
• 239000000126 substance Substances 0.000 description 16
• 208000000668 Chronic Pancreatitis Diseases 0.000 description 15
• 206010033649 Pancreatitis chronic Diseases 0.000 description 15
• 150000001413 amino acids Chemical group 0.000 description 15
• 150000007523 nucleic acids Chemical class 0.000 description 15
• 239000008194 pharmaceutical composition Substances 0.000 description 15
• 125000003277 amino group Chemical group 0.000 description 14
• 238000000338 in vitro Methods 0.000 description 14
• AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 14
• 239000002773 nucleotide Substances 0.000 description 14
• 125000003729 nucleotide group Chemical group 0.000 description 14
• 229910052760 oxygen Inorganic materials 0.000 description 14
• 229910052717 sulfur Inorganic materials 0.000 description 14
• 208000004454 Hyperalgesia Diseases 0.000 description 13
• 102000003567 TRPV4 Human genes 0.000 description 13
• 101150098315 TRPV4 gene Proteins 0.000 description 13
• 238000010171 animal model Methods 0.000 description 13
• 230000003834 intracellular effect Effects 0.000 description 13
• 239000002207 metabolite Substances 0.000 description 13
• 230000001590 oxidative effect Effects 0.000 description 13
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 12
• 208000005232 Glossitis Diseases 0.000 description 12
• 150000001412 amines Chemical class 0.000 description 12
• 125000004429 atom Chemical group 0.000 description 12
• 230000001684 chronic effect Effects 0.000 description 12
• 210000003414 extremity Anatomy 0.000 description 12
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 12
• 102000039446 nucleic acids Human genes 0.000 description 12
• 108020004707 nucleic acids Proteins 0.000 description 12
• 208000033808 peripheral neuropathy Diseases 0.000 description 12
• 238000001356 surgical procedure Methods 0.000 description 12
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 11
• 230000004913 activation Effects 0.000 description 11
• 230000006399 behavior Effects 0.000 description 11
• 208000035475 disorder Diseases 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 238000000554 physical therapy Methods 0.000 description 11
• 239000011591 potassium Substances 0.000 description 11
• 229910052700 potassium Inorganic materials 0.000 description 11
• 208000003265 stomatitis Diseases 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 10
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
• 230000002757 inflammatory effect Effects 0.000 description 10
• 210000004379 membrane Anatomy 0.000 description 10
• 239000012528 membrane Substances 0.000 description 10
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 10
• 210000000496 pancreas Anatomy 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 230000001105 regulatory effect Effects 0.000 description 10
• 150000003384 small molecules Chemical class 0.000 description 10
• 230000008961 swelling Effects 0.000 description 10
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 9
• 208000035154 Hyperesthesia Diseases 0.000 description 9
• 206010033647 Pancreatitis acute Diseases 0.000 description 9
• 241000700159 Rattus Species 0.000 description 9
• 201000003229 acute pancreatitis Diseases 0.000 description 9
• 150000001335 aliphatic alkanes Chemical class 0.000 description 9
• 238000006243 chemical reaction Methods 0.000 description 9
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
• 210000002683 foot Anatomy 0.000 description 9
• 230000036571 hydration Effects 0.000 description 9
• 238000006703 hydration reaction Methods 0.000 description 9
• 230000001965 increasing effect Effects 0.000 description 9
• 235000016709 nutrition Nutrition 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 208000017520 skin disease Diseases 0.000 description 9
• 230000000638 stimulation Effects 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
• 208000007514 Herpes zoster Diseases 0.000 description 8
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
• 125000003710 aryl alkyl group Chemical group 0.000 description 8
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
• IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 8
• 230000033228 biological regulation Effects 0.000 description 8
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 8
• 210000003584 mesangial cell Anatomy 0.000 description 8
• 210000003205 muscle Anatomy 0.000 description 8
• 230000035764 nutrition Effects 0.000 description 8
• 239000001301 oxygen Substances 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• DDOQBQRIEWHWBT-UHFFFAOYSA-N 2-azaniumyl-4-phosphonobutanoate Chemical compound OC(=O)C(N)CCP(O)(O)=O DDOQBQRIEWHWBT-UHFFFAOYSA-N 0.000 description 7
• 201000004384 Alopecia Diseases 0.000 description 7
• 208000024827 Alzheimer disease Diseases 0.000 description 7
• 102000003922 Calcium Channels Human genes 0.000 description 7
• 108090000312 Calcium Channels Proteins 0.000 description 7
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 7
• 206010007134 Candida infections Diseases 0.000 description 7
• 108091005462 Cation channels Proteins 0.000 description 7
• 208000018522 Gastrointestinal disease Diseases 0.000 description 7
• 206010020751 Hypersensitivity Diseases 0.000 description 7
• 208000007027 Oral Candidiasis Diseases 0.000 description 7
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
• 201000003984 candidiasis Diseases 0.000 description 7
• 238000002512 chemotherapy Methods 0.000 description 7
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
• 206010012601 diabetes mellitus Diseases 0.000 description 7
• 235000019441 ethanol Nutrition 0.000 description 7
• 230000002496 gastric effect Effects 0.000 description 7
• 208000024963 hair loss Diseases 0.000 description 7
• 230000003676 hair loss Effects 0.000 description 7
• 125000005842 heteroatom Chemical group 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
• 230000002085 persistent effect Effects 0.000 description 7
• 210000003296 saliva Anatomy 0.000 description 7
• 210000000278 spinal cord Anatomy 0.000 description 7
• 239000011593 sulfur Substances 0.000 description 7
• 125000003396 thiol group Chemical class [H]S* 0.000 description 7
• 230000008733 trauma Effects 0.000 description 7
• 229940088594 vitamin Drugs 0.000 description 7
• 239000011782 vitamin Substances 0.000 description 7
• 208000000412 Avitaminosis Diseases 0.000 description 6
• 241000282414 Homo sapiens Species 0.000 description 6
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
• 241000287411 Turdidae Species 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 125000001931 aliphatic group Chemical group 0.000 description 6
• 229940035676 analgesics Drugs 0.000 description 6
• 239000000730 antalgic agent Substances 0.000 description 6
• 210000000170 cell membrane Anatomy 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 206010013781 dry mouth Diseases 0.000 description 6
• 201000006549 dyspepsia Diseases 0.000 description 6
• 125000000524 functional group Chemical group 0.000 description 6
• 230000014509 gene expression Effects 0.000 description 6
• 230000003779 hair growth Effects 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000010291 membrane polarization Effects 0.000 description 6
• 239000002324 mouth wash Substances 0.000 description 6
• 229940127240 opiate Drugs 0.000 description 6
• 229940005483 opioid analgesics Drugs 0.000 description 6
• 125000003367 polycyclic group Chemical group 0.000 description 6
• 210000004927 skin cell Anatomy 0.000 description 6
• 206010041823 squamous cell carcinoma Diseases 0.000 description 6
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 6
• 102000042565 transient receptor (TC 1.A.4) family Human genes 0.000 description 6
• 108091053409 transient receptor (TC 1.A.4) family Proteins 0.000 description 6
• 230000036269 ulceration Effects 0.000 description 6
• 229930003231 vitamin Natural products 0.000 description 6
• 235000013343 vitamin Nutrition 0.000 description 6
• 208000002874 Acne Vulgaris Diseases 0.000 description 5
• 206010004146 Basal cell carcinoma Diseases 0.000 description 5
• 206010019233 Headaches Diseases 0.000 description 5
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
• 206010061291 Mineral deficiency Diseases 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 229910019142 PO4 Inorganic materials 0.000 description 5
• 208000004550 Postoperative Pain Diseases 0.000 description 5
• 208000003251 Pruritus Diseases 0.000 description 5
• 241000206572 Rhodophyta Species 0.000 description 5
• 102000003563 TRPV Human genes 0.000 description 5
• 108060008564 TRPV Proteins 0.000 description 5
• 102000003565 TRPV2 Human genes 0.000 description 5
• 206010044016 Tooth abscess Diseases 0.000 description 5
• 101150077905 Trpv2 gene Proteins 0.000 description 5
• 206010000496 acne Diseases 0.000 description 5
• 230000003213 activating effect Effects 0.000 description 5
• 239000013543 active substance Substances 0.000 description 5
• 230000032683 aging Effects 0.000 description 5
• 230000007815 allergy Effects 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 239000003242 anti bacterial agent Substances 0.000 description 5
• 230000003542 behavioural effect Effects 0.000 description 5
• 230000009460 calcium influx Effects 0.000 description 5
• 230000004663 cell proliferation Effects 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 201000003515 dental abscess Diseases 0.000 description 5
• 230000002951 depilatory effect Effects 0.000 description 5
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
• 210000003238 esophagus Anatomy 0.000 description 5
• 206010016256 fatigue Diseases 0.000 description 5
• 230000004907 flux Effects 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 150000002430 hydrocarbons Chemical class 0.000 description 5
• 210000000987 immune system Anatomy 0.000 description 5
• 230000008595 infiltration Effects 0.000 description 5
• 238000001764 infiltration Methods 0.000 description 5
• 208000027866 inflammatory disease Diseases 0.000 description 5
• 210000001847 jaw Anatomy 0.000 description 5
• 208000017169 kidney disease Diseases 0.000 description 5
• 208000019423 liver disease Diseases 0.000 description 5
• 230000009245 menopause Effects 0.000 description 5
• 229960005181 morphine Drugs 0.000 description 5
• 230000004770 neurodegeneration Effects 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 230000000926 neurological effect Effects 0.000 description 5
• 230000003040 nociceptive effect Effects 0.000 description 5
• 150000002894 organic compounds Chemical group 0.000 description 5
• 239000010452 phosphate Substances 0.000 description 5
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
• 210000002784 stomach Anatomy 0.000 description 5
• 230000035882 stress Effects 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 5
• 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 5
• UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 4
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 206010005949 Bone cancer Diseases 0.000 description 4
• 208000018084 Bone neoplasm Diseases 0.000 description 4
• 206010006784 Burning sensation Diseases 0.000 description 4
• 241000700198 Cavia Species 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 101000633107 Homo sapiens Transient receptor potential cation channel subfamily V member 3 Proteins 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• 206010021135 Hypovitaminosis Diseases 0.000 description 4
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 208000002720 Malnutrition Diseases 0.000 description 4
• XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
• BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical group C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
• 206010033372 Pain and discomfort Diseases 0.000 description 4
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 241000700605 Viruses Species 0.000 description 4
• 206010047700 Vomiting Diseases 0.000 description 4
• 210000001015 abdomen Anatomy 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 206010000269 abscess Diseases 0.000 description 4
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 4
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
• 208000026935 allergic disease Diseases 0.000 description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
• 230000000202 analgesic effect Effects 0.000 description 4
• 230000003110 anti-inflammatory effect Effects 0.000 description 4
• 208000006673 asthma Diseases 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 210000004556 brain Anatomy 0.000 description 4
• 229910001424 calcium ion Inorganic materials 0.000 description 4
• 235000017663 capsaicin Nutrition 0.000 description 4
• 229960002504 capsaicin Drugs 0.000 description 4
• 150000001768 cations Chemical class 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
• 235000013305 food Nutrition 0.000 description 4
• 231100000869 headache Toxicity 0.000 description 4
• 208000024798 heartburn Diseases 0.000 description 4
• 102000052198 human TRPV3 Human genes 0.000 description 4
• 230000001976 improved effect Effects 0.000 description 4
• 238000000099 in vitro assay Methods 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 208000002551 irritable bowel syndrome Diseases 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000007937 lozenge Substances 0.000 description 4
• 238000007726 management method Methods 0.000 description 4
• 230000028161 membrane depolarization Effects 0.000 description 4
• 229940051866 mouthwash Drugs 0.000 description 4
• SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 4
• 229960004448 pentamidine Drugs 0.000 description 4
• ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 4
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 4
• 150000004060 quinone imines Chemical class 0.000 description 4
• 102000005962 receptors Human genes 0.000 description 4
• 108020003175 receptors Proteins 0.000 description 4
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
• 230000001953 sensory effect Effects 0.000 description 4
• 208000020431 spinal cord injury Diseases 0.000 description 4
• 210000003594 spinal ganglia Anatomy 0.000 description 4
• 210000001032 spinal nerve Anatomy 0.000 description 4
• 239000007921 spray Substances 0.000 description 4
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
• 208000030401 vitamin deficiency disease Diseases 0.000 description 4
• 150000003722 vitamin derivatives Chemical class 0.000 description 4
• 230000008673 vomiting Effects 0.000 description 4
• IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 206010068065 Burning mouth syndrome Diseases 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 3
• 229920000742 Cotton Polymers 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 3
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
• 208000004898 Herpes Labialis Diseases 0.000 description 3
• 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 description 3
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• 208000007101 Muscle Cramp Diseases 0.000 description 3
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
• 108090000699 N-Type Calcium Channels Proteins 0.000 description 3
• 102000004129 N-Type Calcium Channels Human genes 0.000 description 3
• 206010028813 Nausea Diseases 0.000 description 3
• 108091028043 Nucleic acid sequence Proteins 0.000 description 3
• 206010067152 Oral herpes Diseases 0.000 description 3
• 241000721454 Pemphigus Species 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 102000027545 TRPM Human genes 0.000 description 3
• 108091008847 TRPM Proteins 0.000 description 3
• 101150095096 TRPM2 gene Proteins 0.000 description 3
• 239000004098 Tetracycline Substances 0.000 description 3
• 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 description 3
• 208000036142 Viral infection Diseases 0.000 description 3
• 125000005910 alkyl carbonate group Chemical group 0.000 description 3
• 239000013566 allergen Substances 0.000 description 3
• 229940035674 anesthetics Drugs 0.000 description 3
• 230000003042 antagnostic effect Effects 0.000 description 3
• 239000002488 antieczema agent Substances 0.000 description 3
• 229940124584 antitussives Drugs 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 3
• 229960002882 calcipotriol Drugs 0.000 description 3
• 235000020964 calcitriol Nutrition 0.000 description 3
• 239000011612 calcitriol Substances 0.000 description 3
• 230000004094 calcium homeostasis Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 210000000038 chest Anatomy 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 125000000392 cycloalkenyl group Chemical group 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 230000018044 dehydration Effects 0.000 description 3
• 238000006297 dehydration reaction Methods 0.000 description 3
• 208000002925 dental caries Diseases 0.000 description 3
• 229960003957 dexamethasone Drugs 0.000 description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
• 102000038379 digestive enzymes Human genes 0.000 description 3
• 108091007734 digestive enzymes Proteins 0.000 description 3
• 208000010643 digestive system disease Diseases 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 230000005714 functional activity Effects 0.000 description 3
• 239000003193 general anesthetic agent Substances 0.000 description 3
• 208000006454 hepatitis Diseases 0.000 description 3
• 231100000283 hepatitis Toxicity 0.000 description 3
• 210000000548 hind-foot Anatomy 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229930195733 hydrocarbon Natural products 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 210000005061 intracellular organelle Anatomy 0.000 description 3
• 239000002085 irritant Substances 0.000 description 3
• 230000007794 irritation Effects 0.000 description 3
• 230000007803 itching Effects 0.000 description 3
• 238000011813 knockout mouse model Methods 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 235000000824 malnutrition Nutrition 0.000 description 3
• 230000001071 malnutrition Effects 0.000 description 3
• 238000002483 medication Methods 0.000 description 3
• 229960002509 miconazole Drugs 0.000 description 3
• 230000003278 mimic effect Effects 0.000 description 3
• 210000004877 mucosa Anatomy 0.000 description 3
• 230000008693 nausea Effects 0.000 description 3
• 230000001537 neural effect Effects 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 210000000929 nociceptor Anatomy 0.000 description 3
• 208000015380 nutritional deficiency disease Diseases 0.000 description 3
• 230000037324 pain perception Effects 0.000 description 3
• 230000008058 pain sensation Effects 0.000 description 3
• 208000035824 paresthesia Diseases 0.000 description 3
• 230000008447 perception Effects 0.000 description 3
• XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 3
• 230000004962 physiological condition Effects 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 230000000069 prophylactic effect Effects 0.000 description 3
• 150000003180 prostaglandins Chemical class 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 229910001415 sodium ion Inorganic materials 0.000 description 3
• 210000004872 soft tissue Anatomy 0.000 description 3
• 239000000243 solution Substances 0.000 description 3
• 230000002269 spontaneous effect Effects 0.000 description 3
• 230000035900 sweating Effects 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 3
• 229960004907 tacalcitol Drugs 0.000 description 3
• 229960002180 tetracycline Drugs 0.000 description 3
• 235000019364 tetracycline Nutrition 0.000 description 3
• 229930101283 tetracycline Natural products 0.000 description 3
• 150000003522 tetracyclines Chemical class 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 229930192474 thiophene Chemical group 0.000 description 3
• 229960000707 tobramycin Drugs 0.000 description 3
• NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 3
• 239000000606 toothpaste Substances 0.000 description 3
• 230000009385 viral infection Effects 0.000 description 3
• 208000009935 visceral pain Diseases 0.000 description 3
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
• LVLLALCJVJNGQQ-SEODYNFXSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r,3e,5e)-7-ethyl-7-hydroxynona-3,5-dien-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C LVLLALCJVJNGQQ-SEODYNFXSA-N 0.000 description 2
• KLZOTDOJMRMLDX-YBBVPDDNSA-N (1r,3s,5z)-5-[(2e)-2-[(1s,3as,7as)-1-[(1r)-1-(4-ethyl-4-hydroxyhexoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C)OCCCC(O)(CC)CC)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C KLZOTDOJMRMLDX-YBBVPDDNSA-N 0.000 description 2
• DTTONLKLWRTCAB-UDFURZHRSA-N (1s,3e,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2s)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione Chemical compound O=C([C@@]1(C(C)(C)[C@H](CC=C(C)C)C[C@](C2=O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)\C2=C(\O)C1=CC=C(O)C(O)=C1 DTTONLKLWRTCAB-UDFURZHRSA-N 0.000 description 2
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
• RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 2
• LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
• VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 2
• OKQHSIGMOWQUIK-UHFFFAOYSA-N 2-[(2-aminopurin-9-yl)methoxy]ethanol Chemical compound NC1=NC=C2N=CN(COCCO)C2=N1 OKQHSIGMOWQUIK-UHFFFAOYSA-N 0.000 description 2
• DRTQXUJAHCYKQG-UHFFFAOYSA-N 2-diphenylboranylethanamine Chemical compound C=1C=CC=CC=1B(CCN)C1=CC=CC=C1 DRTQXUJAHCYKQG-UHFFFAOYSA-N 0.000 description 2
• LTDCCBLBAQXNKP-SHYZEUOFSA-N 4-amino-1-[(2r,3r,5s)-3-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](F)C[C@@H](CO)O1 LTDCCBLBAQXNKP-SHYZEUOFSA-N 0.000 description 2
• PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 2
• 208000004998 Abdominal Pain Diseases 0.000 description 2
• 206010000087 Abdominal pain upper Diseases 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 208000007848 Alcoholism Diseases 0.000 description 2
• 208000006820 Arthralgia Diseases 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
• 108010078791 Carrier Proteins Proteins 0.000 description 2
• 206010008479 Chest Pain Diseases 0.000 description 2
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 206010016334 Feeling hot Diseases 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
• QDKLRKZQSOQWJQ-JGWHSXGBSA-N Garcinol Natural products O=C([C@@]1(C(C)(C)[C@@H](CC=C(C)C)C[C@](C=2O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)C=2C(=O)C1=CC=C(O)C(O)=C1 QDKLRKZQSOQWJQ-JGWHSXGBSA-N 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 239000000899 Gutta-Percha Substances 0.000 description 2
• 208000031886 HIV Infections Diseases 0.000 description 2
• 208000037357 HIV infectious disease Diseases 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101000605625 Homo sapiens Polycystic kidney disease 2-like 1 protein Proteins 0.000 description 2
• 101000605623 Homo sapiens Polycystic kidney disease 2-like 2 protein Proteins 0.000 description 2
• 101001074439 Homo sapiens Polycystin-2 Proteins 0.000 description 2
• 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 description 2
• 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 description 2
• 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 102000003839 Human Proteins Human genes 0.000 description 2
• 208000023105 Huntington disease Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
• 229930064664 L-arginine Natural products 0.000 description 2
• 235000014852 L-arginine Nutrition 0.000 description 2
• DTXXSJZBSTYZKE-ZDQKKZTESA-N Maxacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](OCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C DTXXSJZBSTYZKE-ZDQKKZTESA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 206010028347 Muscle twitching Diseases 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 208000028389 Nerve injury Diseases 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 229930012538 Paclitaxel Natural products 0.000 description 2
• 240000000342 Palaquium gutta Species 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 208000010886 Peripheral nerve injury Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 102100038330 Polycystic kidney disease 2-like 1 protein Human genes 0.000 description 2
• 102100038335 Polycystic kidney disease 2-like 2 protein Human genes 0.000 description 2
• 102100036142 Polycystin-2 Human genes 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
• BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 206010040880 Skin irritation Diseases 0.000 description 2
• 108060008646 TRPA Proteins 0.000 description 2
• 102000027549 TRPC Human genes 0.000 description 2
• 108060008648 TRPC Proteins 0.000 description 2
• 102000003623 TRPC6 Human genes 0.000 description 2
• 102000003617 TRPM1 Human genes 0.000 description 2
• 102000003615 TRPM2 Human genes 0.000 description 2
• 102000003620 TRPM3 Human genes 0.000 description 2
• 108060008547 TRPM3 Proteins 0.000 description 2
• 102000003618 TRPM4 Human genes 0.000 description 2
• 102000003611 TRPM7 Human genes 0.000 description 2
• 229940123537 TRPM8 antagonist Drugs 0.000 description 2
• 102000027544 TRPML Human genes 0.000 description 2
• 108091008846 TRPML Proteins 0.000 description 2
• 108060009332 TRPP Proteins 0.000 description 2
• 108050001421 Transient receptor potential channel, canonical 6 Proteins 0.000 description 2
• XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
• 206010047627 Vitamin deficiencies Diseases 0.000 description 2
• 102100032574 Voltage-dependent L-type calcium channel subunit alpha-1C Human genes 0.000 description 2
• 102100033024 Voltage-dependent T-type calcium channel subunit alpha-1G Human genes 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
• 229960001138 acetylsalicylic acid Drugs 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
• 208000009621 actinic keratosis Diseases 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000036982 action potential Effects 0.000 description 2
• 125000002015 acyclic group Chemical group 0.000 description 2
• LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 2
• 229960002916 adapalene Drugs 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229960003805 amantadine Drugs 0.000 description 2
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
• 230000003444 anaesthetic effect Effects 0.000 description 2
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
• 230000000843 anti-fungal effect Effects 0.000 description 2
• 239000001961 anticonvulsive agent Substances 0.000 description 2
• 239000003434 antitussive agent Substances 0.000 description 2
• 208000002399 aphthous stomatitis Diseases 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 230000027455 binding Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000006931 brain damage Effects 0.000 description 2
• 231100000874 brain damage Toxicity 0.000 description 2
• 208000029028 brain injury Diseases 0.000 description 2
• GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
• 229960005084 calcitriol Drugs 0.000 description 2
• 230000005907 cancer growth Effects 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 150000001721 carbon Chemical group 0.000 description 2
• 150000007942 carboxylates Chemical class 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000006727 cell loss Effects 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 239000007910 chewable tablet Substances 0.000 description 2
• 229960003260 chlorhexidine Drugs 0.000 description 2
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
• OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 230000008602 contraction Effects 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 239000003246 corticosteroid Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 238000005520 cutting process Methods 0.000 description 2
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• RJGHQTVXGKYATR-UHFFFAOYSA-L dibutyl(dichloro)stannane Chemical compound CCCC[Sn](Cl)(Cl)CCCC RJGHQTVXGKYATR-UHFFFAOYSA-L 0.000 description 2
• 229960002656 didanosine Drugs 0.000 description 2
• 235000005911 diet Nutrition 0.000 description 2
• 230000037213 diet Effects 0.000 description 2
• 230000035622 drinking Effects 0.000 description 2
• 230000002121 endocytic effect Effects 0.000 description 2
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
• 210000001163 endosome Anatomy 0.000 description 2
• AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
• 239000003172 expectorant agent Substances 0.000 description 2
• 230000003419 expectorant effect Effects 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 229960004396 famciclovir Drugs 0.000 description 2
• GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
• 229960001419 fenoprofen Drugs 0.000 description 2
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
• 125000005567 fluorenylene group Chemical group 0.000 description 2
• 239000011724 folic acid Substances 0.000 description 2
• 229960000304 folic acid Drugs 0.000 description 2
• 235000019152 folic acid Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• LMFLOMBYUXRHIL-UHFFFAOYSA-N garcifuran-A Natural products COC1=C(O)C(OC)=CC(C=2C(=C3C=COC3=CC=2)O)=C1 LMFLOMBYUXRHIL-UHFFFAOYSA-N 0.000 description 2
• 208000018685 gastrointestinal system disease Diseases 0.000 description 2
• 208000007565 gingivitis Diseases 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 239000003966 growth inhibitor Substances 0.000 description 2
• 229920000588 gutta-percha Polymers 0.000 description 2
• GRBCIRZXESZBGJ-UHFFFAOYSA-N guttiferone F Natural products CC(=CCCC(C(=C)C)C12CC(CC=C(C)C)C(C)(C)C(CC=C(C)C)(C(=O)C(=C1O)C(=O)c3ccc(O)c(O)c3)C2=O)C GRBCIRZXESZBGJ-UHFFFAOYSA-N 0.000 description 2
• 208000019622 heart disease Diseases 0.000 description 2
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
• OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
• WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
• 229960001410 hydromorphone Drugs 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 231100000021 irritant Toxicity 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
• 229960000991 ketoprofen Drugs 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 229920006008 lipopolysaccharide Polymers 0.000 description 2
• 239000012669 liquid formulation Substances 0.000 description 2
• 239000003589 local anesthetic agent Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 230000036210 malignancy Effects 0.000 description 2
• 229960002510 mandelic acid Drugs 0.000 description 2
• 229960003464 mefenamic acid Drugs 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• HHVOOJDLCVOLKI-VWLOTQADSA-N methyl (2S)-2-(dibenzylamino)-3-(1H-indol-3-yl)propanoate Chemical compound C=1C=CC=CC=1CN([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)OC)CC1=CC=CC=C1 HHVOOJDLCVOLKI-VWLOTQADSA-N 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
• 230000004899 motility Effects 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 230000002107 myocardial effect Effects 0.000 description 2
• DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 2
• 229960002009 naproxen Drugs 0.000 description 2
• CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
• 230000003533 narcotic effect Effects 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 230000008764 nerve damage Effects 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 239000002581 neurotoxin Substances 0.000 description 2
• 231100000618 neurotoxin Toxicity 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 229940100692 oral suspension Drugs 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 229960002739 oxaprozin Drugs 0.000 description 2
• OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• 229960001592 paclitaxel Drugs 0.000 description 2
• 210000000277 pancreatic duct Anatomy 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 125000001151 peptidyl group Chemical group 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 229950001046 piroctone Drugs 0.000 description 2
• QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
• 229960002702 piroxicam Drugs 0.000 description 2
• 108091033319 polynucleotide Proteins 0.000 description 2
• 102000040430 polynucleotide Human genes 0.000 description 2
• 239000002157 polynucleotide Substances 0.000 description 2
• 150000004032 porphyrins Chemical class 0.000 description 2
• 230000035935 pregnancy Effects 0.000 description 2
• 208000037920 primary disease Diseases 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• QUKUNZDPKPLYGS-UHFFFAOYSA-N propanoic acid;1h-pyrrole Chemical compound CCC(O)=O.C=1C=CNC=1 QUKUNZDPKPLYGS-UHFFFAOYSA-N 0.000 description 2
• 235000019260 propionic acid Nutrition 0.000 description 2
• WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
• XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 230000002040 relaxant effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 229960004889 salicylic acid Drugs 0.000 description 2
• 210000001732 sebaceous gland Anatomy 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 239000011669 selenium Substances 0.000 description 2
• 235000019615 sensations Nutrition 0.000 description 2
• 210000001044 sensory neuron Anatomy 0.000 description 2
• 230000020341 sensory perception of pain Effects 0.000 description 2
• 230000035939 shock Effects 0.000 description 2
• 230000036556 skin irritation Effects 0.000 description 2
• 231100000475 skin irritation Toxicity 0.000 description 2
• 210000000813 small intestine Anatomy 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
• 229960000894 sulindac Drugs 0.000 description 2
• 230000009747 swallowing Effects 0.000 description 2
• 230000002889 sympathetic effect Effects 0.000 description 2
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
• 229960000565 tazarotene Drugs 0.000 description 2
• LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 229960003500 triclosan Drugs 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
• 229960004528 vincristine Drugs 0.000 description 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
• 235000019155 vitamin A Nutrition 0.000 description 2
• 239000011719 vitamin A Substances 0.000 description 2
• 229940045997 vitamin a Drugs 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 description 1
• CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
• FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 description 1
• 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
• ZSTLCHCDLIUXJE-ZGBAEQJLSA-N (2S,5S)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride Chemical compound O.Cl.Cl.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2.C1S[C@@H](C)O[C@@]21C(CC1)CCN1C2 ZSTLCHCDLIUXJE-ZGBAEQJLSA-N 0.000 description 1
• RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
• VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
• XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
• RNIADBXQDMCFEN-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-7-chloro-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=C(Cl)C=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O RNIADBXQDMCFEN-IWVLMIASSA-N 0.000 description 1
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
• GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
• QYAPHLRPFNSDNH-MRFRVZCGSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O QYAPHLRPFNSDNH-MRFRVZCGSA-N 0.000 description 1
• KFINXCASWPGHEW-UHFFFAOYSA-N (9S*,10R*,11R*,12Z,15Z)-9,10,11-trihydroxyoctadeca-12,15-dienoic acid Natural products CCC=CCC=CC(O)C(O)C(O)CCCCCCCC(O)=O KFINXCASWPGHEW-UHFFFAOYSA-N 0.000 description 1
• MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
• KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
• IWKXBHQELWQLHF-CAPFRKAQSA-N (ne)-n-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=N\O)\C1=CC=CC=C1 IWKXBHQELWQLHF-CAPFRKAQSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• JGTNAGYHADQMCM-UHFFFAOYSA-M 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JGTNAGYHADQMCM-UHFFFAOYSA-M 0.000 description 1
• GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
• MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
• FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
• UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
• IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 1
• XKKCQTLDIPIRQD-JGVFFNPUSA-N 1-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)CC1 XKKCQTLDIPIRQD-JGVFFNPUSA-N 0.000 description 1
• MKXBOPXRKXGSTI-PJKMHFRUSA-N 1-[(2s,4s,5r)-2-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@]1(F)O[C@H](CO)[C@@H](O)C1 MKXBOPXRKXGSTI-PJKMHFRUSA-N 0.000 description 1
• HBOMLICNUCNMMY-UHFFFAOYSA-N 1-[4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(N=[N+]=[N-])C1 HBOMLICNUCNMMY-UHFFFAOYSA-N 0.000 description 1
• WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
• TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical compound OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 description 1
• WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
• RYDUZJFCKYTEHX-UHFFFAOYSA-N 2-(2-propan-2-yl-2,3-dihydro-1h-inden-5-yl)propanoic acid Chemical compound C1=C(C(C)C(O)=O)C=C2CC(C(C)C)CC2=C1 RYDUZJFCKYTEHX-UHFFFAOYSA-N 0.000 description 1
• JALUUBQFLPUJMY-UHFFFAOYSA-N 2-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 JALUUBQFLPUJMY-UHFFFAOYSA-N 0.000 description 1
• ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
• IRVFGSCWWPVWGV-UHFFFAOYSA-N 2-[2-(2-hydroxy-3-methoxyphenyl)ethenyl]-5,6-dimethyl-3-phenylpyrimidin-4-one Chemical compound COC1=CC=CC(C=CC=2N(C(=O)C(C)=C(C)N=2)C=2C=CC=CC=2)=C1O IRVFGSCWWPVWGV-UHFFFAOYSA-N 0.000 description 1
• OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
• ICHLNDWMYWZUTG-UHFFFAOYSA-N 2-azido-7h-purine Chemical compound [N-]=[N+]=NC1=NC=C2NC=NC2=N1 ICHLNDWMYWZUTG-UHFFFAOYSA-N 0.000 description 1
• UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 description 1
• WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
• WREGKURFCTUGRC-UHFFFAOYSA-N 4-Amino-1-[5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1OC(CO)CC1 WREGKURFCTUGRC-UHFFFAOYSA-N 0.000 description 1
• QDDILOVMGWUNGD-UONOGXRCSA-N 4-[(2S,3R)-4-(1,3-benzodioxol-5-yl)-2,3-dimethylbutyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C[C@H](C)[C@H](C)CC=2C=C3OCOC3=CC=2)=C1 QDDILOVMGWUNGD-UONOGXRCSA-N 0.000 description 1
• GIMSJJHKKXRFGV-BYPJNBLXSA-N 4-amino-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidin-2-one Chemical compound C1=C(I)C(N)=NC(=O)N1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 GIMSJJHKKXRFGV-BYPJNBLXSA-N 0.000 description 1
• JTEGQNOMFQHVDC-RQJHMYQMSA-N 4-amino-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)SC1 JTEGQNOMFQHVDC-RQJHMYQMSA-N 0.000 description 1
• WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
• YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
• OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
• GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 241001535291 Analges Species 0.000 description 1
• 244000099147 Ananas comosus Species 0.000 description 1
• 235000007119 Ananas comosus Nutrition 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 208000019901 Anxiety disease Diseases 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 101100350964 Arabidopsis thaliana PANS1 gene Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 235000007319 Avena orientalis Nutrition 0.000 description 1
• 244000075850 Avena orientalis Species 0.000 description 1
• MZQXAWAWDWCIKG-SPSBLGDNSA-N Avenoleic acid Chemical compound CCC[C@@H](O)C\C=C/C\C=C/CCCCCCCC(O)=O MZQXAWAWDWCIKG-SPSBLGDNSA-N 0.000 description 1
• 108010001478 Bacitracin Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
• 239000004342 Benzoyl peroxide Substances 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• 102100023995 Beta-nerve growth factor Human genes 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 206010070237 Burning feet syndrome Diseases 0.000 description 1
• OUFRHRLDTHNWGD-UHFFFAOYSA-N C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.N2=CN=CC1=CC=CC=C21 Chemical compound C12=CC=C(N1)C=C1C=CC(=N1)C=C1C=CC(N1)=CC=1C=CC(N1)=C2.N2=CN=CC1=CC=CC=C21 OUFRHRLDTHNWGD-UHFFFAOYSA-N 0.000 description 1
• 101150076566 CMR1 gene Proteins 0.000 description 1
• 235000021318 Calcifediol Nutrition 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 108010065839 Capreomycin Proteins 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
• 239000004099 Chlortetracycline Substances 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• 235000005979 Citrus limon Nutrition 0.000 description 1
• 244000131522 Citrus pyriformis Species 0.000 description 1
• BHIHHJWSQVIVOR-RRKCRQDMSA-N ClC(C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O)(Cl)Cl Chemical compound ClC(C=1C(NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C=1)=O)=O)(Cl)Cl BHIHHJWSQVIVOR-RRKCRQDMSA-N 0.000 description 1
• QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 208000003322 Coinfection Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 208000025962 Crush injury Diseases 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 101710112752 Cytotoxin Proteins 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 208000019505 Deglutition disease Diseases 0.000 description 1
• FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
• LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 108010035533 Drosophila Proteins Proteins 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• 206010013786 Dry skin Diseases 0.000 description 1
• 239000010282 Emodin Substances 0.000 description 1
• RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 206010063601 Exposure to extreme temperature Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 206010016059 Facial pain Diseases 0.000 description 1
• 240000008620 Fagopyrum esculentum Species 0.000 description 1
• 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 240000009088 Fragaria x ananassa Species 0.000 description 1
• 208000001034 Frostbite Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• AGJUUQSLGVCRQA-SWOUQTJZSA-N Fungichromin Chemical compound CCCCC[C@@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)[C@@H](O)[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O AGJUUQSLGVCRQA-SWOUQTJZSA-N 0.000 description 1
• 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 206010018286 Gingival pain Diseases 0.000 description 1
• 206010018296 Gingivitis ulcerative Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 241000147041 Guaiacum officinale Species 0.000 description 1
• 208000023329 Gun shot wound Diseases 0.000 description 1
• CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
• 206010019468 Hemiplegia Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000000440 Herpetic Stomatitis Diseases 0.000 description 1
• 101100208030 Homo sapiens TRPV3 gene Proteins 0.000 description 1
• 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 description 1
• 101000844510 Homo sapiens Transient receptor potential cation channel subfamily M member 1 Proteins 0.000 description 1
• 101000844503 Homo sapiens Transient receptor potential cation channel subfamily M member 3 Proteins 0.000 description 1
• 101000844521 Homo sapiens Transient receptor potential cation channel subfamily M member 5 Proteins 0.000 description 1
• 101000844519 Homo sapiens Transient receptor potential cation channel subfamily M member 6 Proteins 0.000 description 1
• 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 240000005979 Hordeum vulgare Species 0.000 description 1
• 235000007340 Hordeum vulgare Nutrition 0.000 description 1
• 206010020590 Hypercalciuria Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
• SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
• 206010023230 Joint stiffness Diseases 0.000 description 1
• 208000000913 Kidney Calculi Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 206010024453 Ligament sprain Diseases 0.000 description 1
• OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 206010067125 Liver injury Diseases 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
• 101150091161 MCOLN1 gene Proteins 0.000 description 1
• QDDILOVMGWUNGD-UHFFFAOYSA-N Macelignan Natural products C1=C(O)C(OC)=CC(CC(C)C(C)CC=2C=C3OCOC3=CC=2)=C1 QDDILOVMGWUNGD-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 244000070406 Malus silvestris Species 0.000 description 1
• ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
• RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
• 206010027603 Migraine headaches Diseases 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 102000007298 Mucin-1 Human genes 0.000 description 1
• 108010008707 Mucin-1 Proteins 0.000 description 1
• 102000007296 Mucin-2 Human genes 0.000 description 1
• 108010008705 Mucin-2 Proteins 0.000 description 1
• 102000007295 Mucin-3 Human genes 0.000 description 1
• 108010008701 Mucin-3 Proteins 0.000 description 1
• 102400001335 Mucolipin Human genes 0.000 description 1
• 102100026502 Mucolipin-1 Human genes 0.000 description 1
• 102100030870 Mucolipin-2 Human genes 0.000 description 1
• 102100030868 Mucolipin-3 Human genes 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101100520164 Mus musculus Pkdrej gene Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
• 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 101100426589 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) trp-3 gene Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 239000004104 Oleandomycin Substances 0.000 description 1
• RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
• UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
• 102400000050 Oxytocin Human genes 0.000 description 1
• XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
• 101800000989 Oxytocin Proteins 0.000 description 1
• 206010033433 Pain in jaw Diseases 0.000 description 1
• UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
• 208000000450 Pelvic Pain Diseases 0.000 description 1
• JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 229930195708 Penicillin V Natural products 0.000 description 1
• AGJUUQSLGVCRQA-UHFFFAOYSA-N Pentamycin Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O AGJUUQSLGVCRQA-UHFFFAOYSA-N 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 208000018262 Peripheral vascular disease Diseases 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 235000014676 Phragmites communis Nutrition 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 108010040201 Polymyxins Proteins 0.000 description 1
• 206010065347 Premenstrual pain Diseases 0.000 description 1
• 206010036618 Premenstrual syndrome Diseases 0.000 description 1
• 102000015499 Presenilins Human genes 0.000 description 1
• 108010050254 Presenilins Proteins 0.000 description 1
• 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 108091030071 RNAI Proteins 0.000 description 1
• 101100047461 Rattus norvegicus Trpm8 gene Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 206010038678 Respiratory depression Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
• 241000208422 Rhododendron Species 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• 229930189077 Rifamycin Natural products 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241001303601 Rosacea Species 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• ZANBLNRUVUOABN-UHFFFAOYSA-N Saururenin Natural products C1=C(OC)C(OC)=CC=C1CC(C)C(C)CC1=CC=C(OCO2)C2=C1 ZANBLNRUVUOABN-UHFFFAOYSA-N 0.000 description 1
• 101100426590 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp2 gene Proteins 0.000 description 1
• 101100100680 Schizosaccharomyces pombe (strain 972 / ATCC 24843) trp4 gene Proteins 0.000 description 1
• 208000008765 Sciatica Diseases 0.000 description 1
• 241000239226 Scorpiones Species 0.000 description 1
• 241000209056 Secale Species 0.000 description 1
• 235000007238 Secale cereale Nutrition 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 206010040954 Skin wrinkling Diseases 0.000 description 1
• 206010041273 Sodium imbalance Diseases 0.000 description 1
• 206010041290 Soft tissue inflammation Diseases 0.000 description 1
• 240000003768 Solanum lycopersicum Species 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 208000029033 Spinal Cord disease Diseases 0.000 description 1
• 239000004187 Spiramycin Substances 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• 102400000096 Substance P Human genes 0.000 description 1
• 101800003906 Substance P Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 229940126495 T-type calcium channel blocker Drugs 0.000 description 1
• 102000003627 TRPC1 Human genes 0.000 description 1
• 101150017559 TRPC1 gene Proteins 0.000 description 1
• 102000003629 TRPC3 Human genes 0.000 description 1
• 102000003622 TRPC4 Human genes 0.000 description 1
• 102000003609 TRPM5 Human genes 0.000 description 1
• 101150059135 TRPM5 gene Proteins 0.000 description 1
• 102000003608 TRPM6 Human genes 0.000 description 1
• 101150045183 TRPM7 gene Proteins 0.000 description 1
• 108010004408 TRPP Cation Channels Proteins 0.000 description 1
• 108010062740 TRPV Cation Channels Proteins 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043269 Tension headache Diseases 0.000 description 1
• 208000008548 Tension-Type Headache Diseases 0.000 description 1
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
• 244000299461 Theobroma cacao Species 0.000 description 1
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
• 241000159243 Toxicodendron radicans Species 0.000 description 1
• 102100031234 Transient receptor potential cation channel subfamily M member 2 Human genes 0.000 description 1
• 102100031229 Transient receptor potential cation channel subfamily M member 3 Human genes 0.000 description 1
• 102100031228 Transient receptor potential cation channel subfamily M member 4 Human genes 0.000 description 1
• 102100031215 Transient receptor potential cation channel subfamily M member 5 Human genes 0.000 description 1
• 102100031232 Transient receptor potential cation channel subfamily M member 7 Human genes 0.000 description 1
• 101710123694 Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
• 102100034030 Transient receptor potential cation channel subfamily M member 8 Human genes 0.000 description 1
• 102100029613 Transient receptor potential cation channel subfamily V member 1 Human genes 0.000 description 1
• 102100029601 Transient receptor potential cation channel subfamily V member 5 Human genes 0.000 description 1
• 108050007112 Transient receptor potential cation channel subfamily V member 5 Proteins 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
• 108010021119 Trichosanthin Proteins 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 101150037542 Trpc3 gene Proteins 0.000 description 1
• 101150099990 Trpc4 gene Proteins 0.000 description 1
• 101150033973 Trpc7 gene Proteins 0.000 description 1
• 101150032671 Trpm1 gene Proteins 0.000 description 1
• 101150111943 Trpm4 gene Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010045171 Tumour pain Diseases 0.000 description 1
• 239000004182 Tylosin Substances 0.000 description 1
• 229930194936 Tylosin Natural products 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 108010059993 Vancomycin Proteins 0.000 description 1
• 206010047095 Vascular pain Diseases 0.000 description 1
• OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
• KBEMFSMODRNJHE-BAJZRUMYSA-N [(2s,4r,5r)-5-(6-aminopurin-9-yl)-4-fluorooxolan-2-yl]methanol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1F KBEMFSMODRNJHE-BAJZRUMYSA-N 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
• 229960000583 acetic acid Drugs 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
• 229960005339 acitretin Drugs 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
• 239000000808 adrenergic beta-agonist Substances 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 206010001584 alcohol abuse Diseases 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 208000025746 alcohol use disease Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
• 229960002535 alfacalcidol Drugs 0.000 description 1
• 125000002723 alicyclic group Chemical group 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 150000001345 alkine derivatives Chemical class 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 150000008051 alkyl sulfates Chemical class 0.000 description 1
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
• IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
• 206010053552 allodynia Diseases 0.000 description 1
• 229940061720 alpha hydroxy acid Drugs 0.000 description 1
• 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• QZNJPJDUBTYMRS-UHFFFAOYSA-M amfenac sodium hydrate Chemical compound O.[Na+].NC1=C(CC([O-])=O)C=CC=C1C(=O)C1=CC=CC=C1 QZNJPJDUBTYMRS-UHFFFAOYSA-M 0.000 description 1
• 229960004821 amikacin Drugs 0.000 description 1
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
• 229960001656 amikacin sulfate Drugs 0.000 description 1
• 125000005021 aminoalkenyl group Chemical group 0.000 description 1
• 125000004103 aminoalkyl group Chemical group 0.000 description 1
• 125000005014 aminoalkynyl group Chemical group 0.000 description 1
• 229960003022 amoxicillin Drugs 0.000 description 1
• LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
• 229940009444 amphotericin Drugs 0.000 description 1
• 229960003942 amphotericin b Drugs 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 230000000954 anitussive effect Effects 0.000 description 1
• 230000003255 anti-acne Effects 0.000 description 1
• 230000003556 anti-epileptic effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940125681 anticonvulsant agent Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 229940030999 antipsoriatics Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 235000021016 apples Nutrition 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 229960001671 azapropazone Drugs 0.000 description 1
• WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
• 229960003071 bacitracin Drugs 0.000 description 1
• 229930184125 bacitracin Natural products 0.000 description 1
• CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 210000000270 basal cell Anatomy 0.000 description 1
• 238000009227 behaviour therapy Methods 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• 238000003339 best practice Methods 0.000 description 1
• 150000001277 beta hydroxy acids Chemical class 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 229910052796 boron Inorganic materials 0.000 description 1
• 230000001680 brushing effect Effects 0.000 description 1
• 210000005178 buccal mucosa Anatomy 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
• 229960001113 butorphanol Drugs 0.000 description 1
• JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
• 229960004361 calcifediol Drugs 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 230000028956 calcium-mediated signaling Effects 0.000 description 1
• 229960004348 candicidin Drugs 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 208000020670 canker sore Diseases 0.000 description 1
• 229960004602 capreomycin Drugs 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
• 229960005286 carbaryl Drugs 0.000 description 1
• 229960003669 carbenicillin Drugs 0.000 description 1
• FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 230000009084 cardiovascular function Effects 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• FUBBGQLTSCSAON-PBFPGSCMSA-N cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 description 1
• 229950004030 cefaloglycin Drugs 0.000 description 1
• CZTQZXZIADLWOZ-CRAIPNDOSA-N cefaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 description 1
• 229960003866 cefaloridine Drugs 0.000 description 1
• XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
• 229960000603 cefalotin Drugs 0.000 description 1
• 229960004350 cefapirin Drugs 0.000 description 1
• 229960001139 cefazolin Drugs 0.000 description 1
• MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
• 229960002588 cefradine Drugs 0.000 description 1
• 229960000590 celecoxib Drugs 0.000 description 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 238000010868 cell confinement Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000009134 cell regulation Effects 0.000 description 1
• 230000010001 cellular homeostasis Effects 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 229940106164 cephalexin Drugs 0.000 description 1
• ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
• RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
• 235000013339 cereals Nutrition 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• WUTYZMFRCNBCHQ-PSASIEDQSA-N cevimeline Chemical compound C1S[C@H](C)O[C@]21C(CC1)CCN1C2 WUTYZMFRCNBCHQ-PSASIEDQSA-N 0.000 description 1
• 229960001314 cevimeline Drugs 0.000 description 1
• 235000013351 cheese Nutrition 0.000 description 1
• SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 229910052729 chemical element Inorganic materials 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 230000001055 chewing effect Effects 0.000 description 1
• 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
• CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
• WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 description 1
• 229960004736 chloroxine Drugs 0.000 description 1
• 229960004475 chlortetracycline Drugs 0.000 description 1
• CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
• 235000019365 chlortetracycline Nutrition 0.000 description 1
• 235000019219 chocolate Nutrition 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000023819 chronic asthma Diseases 0.000 description 1
• 208000013116 chronic cough Diseases 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• 229940117916 cinnamic aldehyde Drugs 0.000 description 1
• KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
• 229960003405 ciprofloxacin Drugs 0.000 description 1
• YLHJFOAQDDQFIU-UHFFFAOYSA-N circulin Chemical compound CCC(C)C1NC(=O)C(CC(C)C)NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC(=O)C(NC(=O)C(CCN)NC=O)C(C)O)CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC1=O YLHJFOAQDDQFIU-UHFFFAOYSA-N 0.000 description 1
• 108010002696 circulin Proteins 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 210000000078 claw Anatomy 0.000 description 1
• 229960002227 clindamycin Drugs 0.000 description 1
• 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
• 229960005228 clioquinol Drugs 0.000 description 1
• 229960003326 cloxacillin Drugs 0.000 description 1
• LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
• 229940047766 co-trimoxazole Drugs 0.000 description 1
• FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
• 229960004126 codeine Drugs 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 208000010877 cognitive disease Diseases 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 230000009989 contractile response Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 235000013365 dairy product Nutrition 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 239000000850 decongestant Substances 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 229960002398 demeclocycline Drugs 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 229950000330 desciclovir Drugs 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 description 1
• 229960003461 dezocine Drugs 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 150000001993 dienes Chemical class 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
• 229960000616 diflunisal Drugs 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
• FPIPGXGPPPQFEQ-DPZDGVIMSA-N dihydroretinol Natural products CC(=CCO)C=CC=C(C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-DPZDGVIMSA-N 0.000 description 1
• 229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 229960000413 doxercalciferol Drugs 0.000 description 1
• HKXBNHCUPKIYDM-CGMHZMFXSA-N doxercalciferol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C HKXBNHCUPKIYDM-CGMHZMFXSA-N 0.000 description 1
• 229960003722 doxycycline Drugs 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 229940112141 dry powder inhaler Drugs 0.000 description 1
• 230000037336 dry skin Effects 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 210000001198 duodenum Anatomy 0.000 description 1
• LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
• VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
• 230000006397 emotional response Effects 0.000 description 1
• 238000001839 endoscopy Methods 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 229950008161 enviroxime Drugs 0.000 description 1
• 210000001339 epidermal cell Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 229960002061 ergocalciferol Drugs 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 229960003203 erythromycin estolate Drugs 0.000 description 1
• AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
• 229960000285 ethambutol Drugs 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
• 229960002767 ethosuximide Drugs 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 229960005293 etodolac Drugs 0.000 description 1
• XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
• HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
• 229960002199 etretinate Drugs 0.000 description 1
• 229940062770 evoxac Drugs 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 239000003885 eye ointment Substances 0.000 description 1
• 229940043259 farnesol Drugs 0.000 description 1
• 229930002886 farnesol Natural products 0.000 description 1
• 210000003195 fascia Anatomy 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000005002 female reproductive tract Anatomy 0.000 description 1
• 201000000182 femoral cancer Diseases 0.000 description 1
• ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
• 229950003564 fiacitabine Drugs 0.000 description 1
• 229950008802 fialuridine Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 229960004273 floxacillin Drugs 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960002390 flurbiprofen Drugs 0.000 description 1
• SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
• 239000013568 food allergen Substances 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 239000008098 formaldehyde solution Substances 0.000 description 1
• 238000001640 fractional crystallisation Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 235000012055 fruits and vegetables Nutrition 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
• 208000001130 gallstones Diseases 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001156 gastric mucosa Anatomy 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000003209 gene knockout Methods 0.000 description 1
• 230000009368 gene silencing by RNA Effects 0.000 description 1
• 102000054767 gene variant Human genes 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 231100000852 glomerular disease Toxicity 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 229950006191 gluconic acid Drugs 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 229960004905 gramicidin Drugs 0.000 description 1
• ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229940091561 guaiac Drugs 0.000 description 1
• 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
• 238000011554 guinea pig model Methods 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 229940124563 hair growth stimulant Drugs 0.000 description 1
• 229960001906 haloprogin Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 231100000234 hepatic damage Toxicity 0.000 description 1
• ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
• 229960004068 hexachlorophene Drugs 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 230000001632 homeopathic effect Effects 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 235000021268 hot food Nutrition 0.000 description 1
• LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
• 229960000240 hydrocodone Drugs 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 150000001261 hydroxy acids Chemical class 0.000 description 1
• MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 1
• 229940005608 hypericin Drugs 0.000 description 1
• PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 238000009802 hysterectomy Methods 0.000 description 1
• CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960004716 idoxuridine Drugs 0.000 description 1
• 150000002466 imines Chemical class 0.000 description 1
• 125000005298 iminyl group Chemical group 0.000 description 1
• 230000000899 immune system response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 208000018879 impaired coordination Diseases 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 201000006747 infectious mononucleosis Diseases 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000010262 intracellular communication Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 229950000704 isoprofen Drugs 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 229960005280 isotretinoin Drugs 0.000 description 1
• 210000001503 joint Anatomy 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
• 229960002064 kanamycin sulfate Drugs 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 150000004715 keto acids Chemical class 0.000 description 1
• OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 150000002596 lactones Chemical class 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 229950006761 lexacalcitol Drugs 0.000 description 1
• 201000011486 lichen planus Diseases 0.000 description 1
• 210000003041 ligament Anatomy 0.000 description 1
• OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
• 229960005287 lincomycin Drugs 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 230000008818 liver damage Effects 0.000 description 1
• KBEMFSMODRNJHE-JFWOZONXSA-N lodenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@@H]1F KBEMFSMODRNJHE-JFWOZONXSA-N 0.000 description 1
• 235000015263 low fat diet Nutrition 0.000 description 1
• 230000001050 lubricating effect Effects 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229940041033 macrolides Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 229950006319 maxacalcitol Drugs 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 229960000826 meclocycline Drugs 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 201000006844 melanomatosis Diseases 0.000 description 1
• 230000012241 membrane hyperpolarization Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• 229940042016 methacycline Drugs 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960003900 methenamine hippurate Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 229960003085 meticillin Drugs 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 229960002421 minocycline hydrochloride Drugs 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 230000001095 motoneuron effect Effects 0.000 description 1
• IYIYMCASGKQOCZ-DJRRULDNSA-N motretinide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C IYIYMCASGKQOCZ-DJRRULDNSA-N 0.000 description 1
• 229960005406 motretinide Drugs 0.000 description 1
• 210000002200 mouth mucosa Anatomy 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 229960003128 mupirocin Drugs 0.000 description 1
• 229930187697 mupirocin Natural products 0.000 description 1
• DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
• 229960000515 nafcillin Drugs 0.000 description 1
• 229960000805 nalbuphine Drugs 0.000 description 1
• NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
• 229940053050 neomycin sulfate Drugs 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 230000008555 neuronal activation Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 229960000689 nevirapine Drugs 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
• 229960001907 nitrofurazone Drugs 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
• 229960001180 norfloxacin Drugs 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000014571 nuts Nutrition 0.000 description 1
• VQOXZBDYSJBXMA-RKEBNKJGSA-N nystatin a1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@@H]1OC1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C[C@](O)(CC(O)C2C(O)=O)OC2C1 VQOXZBDYSJBXMA-RKEBNKJGSA-N 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
• 235000019367 oleandomycin Nutrition 0.000 description 1
• 229960002351 oleandomycin Drugs 0.000 description 1
• 229940069265 ophthalmic ointment Drugs 0.000 description 1
• 238000011369 optimal treatment Methods 0.000 description 1
• 229940041672 oral gel Drugs 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
• 229960001019 oxacillin Drugs 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960002085 oxycodone Drugs 0.000 description 1
• 125000004430 oxygen atom Chemical group O* 0.000 description 1
• 229960005118 oxymorphone Drugs 0.000 description 1
• 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
• XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
• 229960001723 oxytocin Drugs 0.000 description 1
• LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
• 229940124583 pain medication Drugs 0.000 description 1
• 208000005877 painful neuropathy Diseases 0.000 description 1
• 210000003254 palate Anatomy 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 229960000987 paricalcitol Drugs 0.000 description 1
• BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
• UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
• 229960001914 paromomycin Drugs 0.000 description 1
• 229960005065 paromomycin sulfate Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229960001179 penciclovir Drugs 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 229940056360 penicillin g Drugs 0.000 description 1
• 229940056367 penicillin v Drugs 0.000 description 1
• 229960000339 pentamycin Drugs 0.000 description 1
• 229960005301 pentazocine Drugs 0.000 description 1
• VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
• JGTNAGYHADQMCM-UHFFFAOYSA-N perfluorobutanesulfonic acid Chemical group OS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F JGTNAGYHADQMCM-UHFFFAOYSA-N 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
• 229960004894 pheneticillin Drugs 0.000 description 1
• 229950000688 phenothiazine Drugs 0.000 description 1
• BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 125000005496 phosphonium group Chemical group 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
• 229960005330 pimecrolimus Drugs 0.000 description 1
• OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 description 1
• BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
• 229940068196 placebo Drugs 0.000 description 1
• 239000000902 placebo Substances 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 229940124606 potential therapeutic agent Drugs 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
• 229960001233 pregabalin Drugs 0.000 description 1
• 206010036596 premature ejaculation Diseases 0.000 description 1
• 206010036601 premature menopause Diseases 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 150000005599 propionic acid derivatives Chemical class 0.000 description 1
• 230000004952 protein activity Effects 0.000 description 1
• SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 229940079877 pyrogallol Drugs 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000012481 regulation of membrane potential Effects 0.000 description 1
• 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 210000003660 reticulum Anatomy 0.000 description 1
• 150000004492 retinoid derivatives Chemical class 0.000 description 1
• 102000027483 retinoid hormone receptors Human genes 0.000 description 1
• 108091008679 retinoid hormone receptors Proteins 0.000 description 1
• 229960003471 retinol Drugs 0.000 description 1
• 235000020944 retinol Nutrition 0.000 description 1
• 239000011607 retinol Substances 0.000 description 1
• WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
• 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229960000329 ribavirin Drugs 0.000 description 1
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229960003292 rifamycin Drugs 0.000 description 1
• HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
• 229960000888 rimantadine Drugs 0.000 description 1
• 229940106904 rocaltrol Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• HMEYVGGHISAPJR-IAHYZSEUSA-N rolitetracycline Chemical compound O=C([C@@]1(O)C(O)=C2[C@@H]([C@](C3=CC=CC(O)=C3C2=O)(C)O)C[C@H]1[C@@H](C=1O)N(C)C)C=1C(=O)NCN1CCCC1 HMEYVGGHISAPJR-IAHYZSEUSA-N 0.000 description 1
• 229960005009 rolitetracycline Drugs 0.000 description 1
• 201000004700 rosacea Diseases 0.000 description 1
• 229940063635 salagen Drugs 0.000 description 1
• 150000003902 salicylic acid esters Chemical class 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000007423 screening assay Methods 0.000 description 1
• 229950004400 secalciferol Drugs 0.000 description 1
• 229940125723 sedative agent Drugs 0.000 description 1
• 239000000932 sedative agent Substances 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 229950009921 seocalcitol Drugs 0.000 description 1
• 235000015170 shellfish Nutrition 0.000 description 1
• 206010040560 shock Diseases 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 230000012232 skeletal muscle contraction Effects 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 210000001584 soft palate Anatomy 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 229960000268 spectinomycin Drugs 0.000 description 1
• UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
• 210000005070 sphincter Anatomy 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 235000019372 spiramycin Nutrition 0.000 description 1
• 229960001294 spiramycin Drugs 0.000 description 1
• 229930191512 spiramycin Natural products 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 229940114926 stearate Drugs 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 230000003637 steroidlike Effects 0.000 description 1
• 235000021012 strawberries Nutrition 0.000 description 1
• 229960002385 streptomycin sulfate Drugs 0.000 description 1
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
• FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 125000005555 sulfoximide group Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 150000008053 sultones Chemical class 0.000 description 1
• FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
• 229960005314 suramin Drugs 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 206010042772 syncope Diseases 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 208000006379 syphilis Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000011521 systemic chemotherapy Methods 0.000 description 1
• 239000002462 tachykinin receptor antagonist Substances 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 208000001189 temporomandibular joint dysfunction syndrome Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 230000003685 thermal hair damage Effects 0.000 description 1
• 239000003451 thiazide diuretic agent Substances 0.000 description 1
• 125000004149 thio group Chemical group *S* 0.000 description 1
• DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
• 150000003566 thiocarboxylic acids Chemical class 0.000 description 1
• 125000000101 thioether group Chemical group 0.000 description 1
• 230000006016 thyroid dysfunction Effects 0.000 description 1
• 229940110851 tolazine Drugs 0.000 description 1
• JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
• 229960004880 tolnaftate Drugs 0.000 description 1
• 230000001256 tonic effect Effects 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 229940034610 toothpaste Drugs 0.000 description 1
• 239000008009 topical excipient Substances 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 230000036410 touch Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
• LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 150000003852 triazoles Chemical group 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
• VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 1
• 229960003962 trifluridine Drugs 0.000 description 1
• 210000000427 trigeminal ganglion Anatomy 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
• 235000019801 trisodium phosphate Nutrition 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 101150079396 trpC2 gene Proteins 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000005514 two-phase flow Effects 0.000 description 1
• WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
• 229960004059 tylosin Drugs 0.000 description 1
• 235000019375 tylosin Nutrition 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
• 229960003165 vancomycin Drugs 0.000 description 1
• MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 229960003636 vidarabine Drugs 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 235000010374 vitamin B1 Nutrition 0.000 description 1
• 239000011691 vitamin B1 Substances 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 235000019164 vitamin B2 Nutrition 0.000 description 1
• 239000011716 vitamin B2 Substances 0.000 description 1
• 235000019158 vitamin B6 Nutrition 0.000 description 1
• 239000011726 vitamin B6 Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 235000001892 vitamin D2 Nutrition 0.000 description 1
• 239000011653 vitamin D2 Substances 0.000 description 1
• MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
• 235000005282 vitamin D3 Nutrition 0.000 description 1
• QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
• 239000011647 vitamin D3 Substances 0.000 description 1
• 229940021056 vitamin d3 Drugs 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 230000037303 wrinkles Effects 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1